English | 简体中文 | 繁體中文 | 한국어 | 日本語
2023年4月11日 9時00分 JST
Share:
TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50%

ニューヨーク, 2023年4月11日 - (JCN Newswire) - The award-winning TrialWire(TM) Patient Recruitment Platform, the most secure and rapid digital patient recruitment solution to reverse failing recruitment, today announced the rollout of Pre-recruit, the pre-recruitment solution that guarantees success before your study starts.

Pre-recruit ensures study sites have patients to contact as soon as the sites are activated, saving weeks or even months on a clinical program. Real-world data shows Pre-recruit cuts recruitment time by more than 50% saving costs and de-risking studies from the start. Using Pre-recruit sites can have a specific number of AI-Match screened eligible patients ready to contact. Sponsors, CROs, or sites can decide on how many patients each site can manage on activation which is pre-set on the Platform. With Pre-recruit, eligible patients are found online, AI-Match screened, and sent to dedicated and secure study site portals in Salesforce Health Cloud ready to be contacted by Study Coordinators when sites are activated.

Our SMS/Text Patient Engagement System ensures patients are retained by managing patient expectations around contact time with auto-reminders saying a Study Coordinator will contact them shortly. The SMS/Text Patient Engagement System is a world first in speed, security, and compliance for Study Coordinators contacting patients to discuss their study application and site bookings. It is primarily designed to speed up the contact process which is typically delayed using phone or email. Up to 50% of patients can be lost due to contact failure because they often don't answer an unknown number call from a site. In addition, study coordinators often can't afford the time to call more than 3-4 times in the hope of connecting with the patient.

TrialWire has found from patient responses that 92% want to be contacted by SMS/Text so this was a driving force behind the development and rollout of the service. This includes studies for older people. The SMS/Text Patient Engagement System can support all languages and keeps a record in the study coordinator's Dashboard of all conversations.

Most study coordinators are using the contact system to arrange then confirm times for screening calls, or site screening visits.

TrialWire recruitment can start in under 24-hours because the Platform doesn't require approvals.

The TrialWire Technology Platform includes:

- Dedicated secure portal dashboards for each Study Coordinator where they can review patient details and medical information
- Multiple dashboards per site so all Study Coordinators can connect with patients and see real-time progress
- Dashboards for sponsors and CROs where they can see de-identified referral status data
- Secure SMS/Text Patient Engagement System for SCs inside their dashboards for instant communications with the patient - book calls and screening visits
- Automated AI-Match and algorithm-driven "find and screen" patients process
- Minute-by-minute metrics for Study Coordinators showing numbers referred, contacted, screened, and enrolled at their site
- Minute-by-minute metrics for sponsors and CROs showing numbers referred, contacted, screened, and enrolled - across all sites on a study
- HIPAA compliance and all patient privacy security
- Built on the Salesforce Health Cloud
- Unlimited number of sites globally
- Available in all languages
- ScreenMatch - the SC support system that helps contact and phone screen patients

With more than 80% of clinical trials failing to recruit patients on time, and 30% of research sites not able to meet enrollment goals - 10% of sites don't enroll any patients - TrialWire offers peace of mind for sponsors and their CROs.

TrialWire is ideal for sponsors and CROs wanting to avoid extended recruitment delays.

Request more information here - starts in 24 hours https://trial-wire.com/contact/
Learn more here https://www.trial-wire.com/

About TrialWire www.trial-wire.com

TrialWire is a privately held technology company that leverages 25 years of experience in the clinical trial patient recruitment sector. TrialWire, which is solving the most serious problem in the drug development sector.

Its mission is to end the patient recruitment crisis delaying the development of new therapies which is costing drug companies billions of dollars a day due to problems finding the right people quickly and enrolling them at the site level.

The TrialWire Platform is the most secure service (powered by Salesforce Health Cloud) that uses advanced algorithms to find the right people who are online that might be suitable for studies available on the Platform. They are invited into the Platform and taken through the AI-Match screener to determine an exact match to a study - site-based or remote/virtual. No account sign-up is required to find and apply for a study. The Platform ingests study data from approved trial registries like ClinicalTrials.Gov. It uses advanced online algorithms to find patient/trial matches based on detailed demographic and location profiles.

Key to the TrialWire success is that it finds motivated people who are actively online trying to find out more about their conditions. They can be connected to a site in under 2 minutes. These people have high retention rates. Unlike all other digital recruitment firms, TrialWire does NOT keep patient details once a study is completed - no databases so no potential privacy breaches. Sponsors are not paying for database building where patients are sent to other studies.

トピック: Press release summary
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
UK advertising reports GBP36.6bn spend in 2023 
Apr 26, 2024 18:30 HKT/SGT
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project 
Apr 26, 2024 14:34 HKT/SGT
スパークス・グループによる「宇宙フロンティア2号ファンド」の設立について 
Apr 26, 2024 14:00 HKT/SGT
トヨタ、2023年度 販売・生産・輸出実績を発表 
Apr 25, 2024 16:16 HKT/SGT
《"株のアルゴリズム取引"を個人投資家も実現可能に!》 株の自動売買アプリ「Trade Stand(トレスタ)」が 大幅アップデートを発表 
Apr 25, 2024 12:00 HKT/SGT
三菱重工、タイの超大型複合火力発電所プロジェクトでM701JAC形GTCCの7系列目が運転開始 
Apr 24, 2024 14:30 HKT/SGT
トヨタ・モビリティ基金、「自転車事故削減に向けた新たな官民連携のあり方」に関するシンポジウムを開催 
Apr 24, 2024 14:00 HKT/SGT
Honda、新型SUV「WR-V」受注状況について 
Apr 24, 2024 10:00 HKT/SGT
三菱みなとみらい技術館に「空・宇宙ゾーン」を新設、リニューアルオープン 
Apr 24, 2024 10:00 HKT/SGT
China Medical System: New Drug Application of Desidustat Tablets Accepted in China 
Apr 23, 2024 23:06 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575